Akums Drugs and Pharmaceuticals announced its financial results for the second quarter of fiscal year 2027 (Q2 FY27). The company reported a significant year-over-year revenue increase of 31.9%, reaching ₹1,342 crore. EBITDA also saw a substantial jump of 106.1% to ₹195 crore. Profit After Tax (PAT) surged by an impressive 168.3% to ₹115 crore. The CDMO segment continued to be the primary growth driver, contributing 83.1% to the total revenue.
Akums Drugs and Pharmaceuticals Releases Q2 FY27 Financial Highlights
Akums Drugs and Pharmaceuticals has disclosed its financial performance for the second quarter ending September 30, 2026 (Q2 FY27). The company has demonstrated robust growth across key financial metrics.
Consolidated Performance Highlights
- Total Income: Reported at ₹1,371 crore, marking a 30.6% increase year-over-year.
- EBITDA: Reached ₹224 crore (including other income), a substantial rise of 76.3% compared to the previous year.
- Profit After Tax (PAT): Skyrocketed by 168.3% to ₹115 crore.
Operating Performance
- Revenue: Stood at ₹1,342 crore, reflecting a strong year-over-year growth of 31.9%.
- EBITDA: Recorded at ₹195 crore, a significant increase of 106.1% from the prior year.
- PAT: Also showed strong growth at ₹115 crore, up 168.3% year-over-year.
Segment Break-up (Share in Revenue)
- CDMO: Dominant segment, contributing 83.1% to revenue.
- Domestic Branded Formulation: 9.8% share.
- International Branded Formulation: 3.3% share.
- API: 2.1% share.
- Trade Generics: 1.7% share.
H1 FY27 Performance Overview
For the first half of fiscal year 2027 (H1 FY27), Akums Drugs and Pharmaceuticals reported:
- Total Income: ₹2,568 crore (+22.3% YoY).
- EBITDA: ₹429 crore (+51.7% YoY).
- PAT: ₹216 crore (+100.7% YoY).
The presentation also detailed the company’s manufacturing capabilities, historical milestones, and key performance trends, emphasizing strong growth in CDMO and API segments, with strategic focus on expanding international markets.
Source: BSE
